News | May 08, 2026
Lupin Q4 FY26 PBT jumps 115% to Rs 19,280 million
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
Sanplatec is leading the industry in the field of containers and devices for cell culture and live transport
Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
Subscribe To Our Newsletter & Stay Updated
